Transplacental immune modulation with a bacterial-derived agent protects against allergic airway inflammation

  Research In-Press Preview Cell biology Immunology Free access | 10.1172/JCI12263 

Kyle T. Mincham, Naomi M. Scott, Jean-Francois Lauzon-Joset, Jonatan Leffler, Alexander N. Larcombe, Philip A. Stumbles, Sarah A. Robertson, Christian Pasquali, Patrick G. Holt, and Deborah H. Strickland

Abstract

Chronic allergic inflammatory diseases are a major cause of morbidity, allergic asthma alone affecting over 300 million people worldwide. Epidemiological studies demonstrate that environmental stimuli are associated with either promotion or prevention of disease. Major reductions in asthma prevalence are documented in European and US farming communities. Protection is associated with exposure of mothers during pregnancy to microbial breakdown products present in farm dusts and unprocessed foods, and enhancement of innate immune competence in the children. We sought to develop a scientific rationale for progressing these findings towards clinical application for primary disease prevention. Treatment of pregnant mice with a defined clinically-approved immune-modulator was shown to markedly reduce susceptibility of their offspring to development of the hallmark clinical features of allergic airway inflammatory disease. Mechanistically, offspring displayed enhanced dendritic cell-dependent airway mucosal immune surveillance function, which resulted in more efficient generation of mucosal-homing T-regulatory cells in response to local inflammatory challenge. We provide evidence that the principal target for maternal treatment effects was the fetal dendritic cell progenitor compartment, equipping the offspring for accelerated functional maturation of the airway mucosal dendritic cell network following birth. These data provide proof-of-concept supporting the rationale for development of transplacental immune reprogramming approaches for primary disease prevention.

View PDF Adobe pdf file icon

(You must be logged in to add and reply comments)

Interasma on Twitter

Interasma RT @Aller_MD: Subcutaneous immunotherapy induces alterations in monocytes and dendritic cells homeostasis in allergic rhinitis patients htt…
3hreplyretweetfavorite
Interasma RT @Aller_MD: Top story: @SeattleMamaDoc: '“Air Canada doesn’t have epi on board” (apparently too expensive - huh). Thankfully most food-al…
3hreplyretweetfavorite
Interasma Interasma - Effects of Macrolide Treatment during the Hospitalization of Children with Childhood Wheezing Disease:… https://t.co/XLMhnvQl5E
4hreplyretweetfavorite
Interasma RT @ARIAGuideline: Towards precision medicine in chronic rhinosinusitis. Prof. Dr. Benjamin Bleier, USA. https://t.co/ps5LKfOD6H
9hreplyretweetfavorite
Interasma RT @ARIAGuideline: First-line and second-line treatments for chronic sinusitis. An interview with Prof. Peter Hellings, Belgium https://t.c…
9hreplyretweetfavorite

Editor: Juan C. Ivancevich, MD

Copyright © Interasma 2003-2017  •  Terms of Use  •  Privacy Policy  •  Contact Us  •  Sitemap

Powered by FREI SA

InterAsma